Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
13.79
-0.44 (-3.09%)
After Hours: 13.87 +0.08 (0.58%)
Apr 23, 6:26PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.62 - 14.48
52 week 6.61 - 17.46
Open 14.48
Vol / Avg. 1.68M/3.44M
Mkt cap 1.25B
P/E     -
Div/yield     -
EPS -0.57
Shares 90.91M
Beta 4.19
Inst. own 61%
May 5, 2014
Q1 2014 Keryx Biopharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 Keryx Biopharmaceuticals, Inc. Earnings Conference Call - Webcast
Mar 12, 2014
Q4 2013 Keryx Biopharmaceuticals, Inc. Earnings Release
Mar 10, 2014
Keryx Biopharmaceuticals, Inc. at ROTH Conference - Webcast
Mar 3, 2014
Keryx Biopharmaceuticals, Inc. at Cowen Health Care Conference - Webcast
Feb 10, 2014
Keryx Biopharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -667.60%
Operating margin - -672.61%
EBITD margin - -671.84%
Return on average assets -104.34% -117.81%
Return on average equity -136.32% -167.22%
Employees 41 -
CDP Score - -

Address

750 LEXINGTON AVENUE
NEW YORK, NY 10022
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Keryx Biopharmaceuticals, Inc. (Keryx) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease. The Company is developing KRX-0502, an investigational, ferric citrate, oral compound that binds to phosphate. Under the name Zerenex, KRX-0502 has completed a United States-based Phase III clinical program for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Ron Bentsur Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
James F. Oliviero III Chief Financial Officer, Treasurer, Corporate Secretary
Age: 37
Bio & Compensation  - Reuters
Gregory P. Madison Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Bio & Compensation  - Reuters
Thomas M. Edwards Vice President - US Sales
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
Daniel W. Olmstead Vice President - Payer Access
Bio & Compensation  - Reuters
Amit Sharma M.D. Vice President - Medical Affairs
Bio & Compensation  - Reuters
Amy B. Sullivan Vice President - Corporate Development and Public Affairs
Bio & Compensation  - Reuters